Literature DB >> 8827132

Melatonin efficacy in aviation missions requiring rapid deployment and night operations.

C A Comperatore1, H R Lieberman, A W Kirby, B Adams, J S Crowley.   

Abstract

BACKGROUND: The rapid deployment of Army aviation personnel across time zones, combined with missions beginning immediately upon arrival, results in desynchronization of physiological and cognitive performance rhythms. Implementation of effective countermeasures enhances safety, health, well-being, and mission completion. The naturally occurring hormone melatonin has been suggested as an effective counter measure for jet lag and shift lag because of its influence on the human circadian timing system and its hypnotic properties.
METHODS: The efficacy of melatonin (10 mg) in maintaining stable sleep/wake cycles of Army aircrews was tested during a training mission involving rapid deployment to the Middle East and night operations. Cognitive performance was tested before and after travel; activity rhythms were recorded continuously for 13 d.
RESULTS: Melatonin treatment advanced both bedtimes and rise times (2-3 h) and maintained sleep durations between 7-8 h. Placebo treatment was mostly associated with longer advances in rise times than bedtimes resulting in shorter sleep durations (5-7 h). Upon awakening, the melatonin group exhibited significantly fewer errors (mean: 7.45) than the placebo group (mean: 14.50) in a dual-task vigilance test.
CONCLUSION: Melatonin can be a useful treatment for the prevention of sleep disruptions and cognitive degradation, even in uncontrolled sleeping environments characteristic of military deployments.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8827132

Source DB:  PubMed          Journal:  Aviat Space Environ Med        ISSN: 0095-6562


  9 in total

Review 1.  Jet-lag and shift work: (2). Therapeutic use of melatonin.

Authors:  J Arendt
Journal:  J R Soc Med       Date:  1999-08       Impact factor: 5.344

Review 2.  Melatonin and jet lag.

Authors:  J Waterhouse; T Reilly; G Atkinson
Journal:  Br J Sports Med       Date:  1998-06       Impact factor: 13.800

Review 3.  Circadian rhythm sleep disorders: pathophysiology and potential approaches to management.

Authors:  N Zisapel
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

4.  Cardiovascular effects of melatonin in hypertensive patients well controlled by nifedipine: a 24-hour study.

Authors:  P Lusardi; E Piazza; R Fogari
Journal:  Br J Clin Pharmacol       Date:  2000-05       Impact factor: 4.335

5.  How To Travel the World Without Jet lag.

Authors:  Charmane I Eastman; Helen J Burgess
Journal:  Sleep Med Clin       Date:  2009-06-01

Review 6.  Practice parameters for the clinical evaluation and treatment of circadian rhythm sleep disorders. An American Academy of Sleep Medicine report.

Authors:  Timothy I Morgenthaler; Teofilo Lee-Chiong; Cathy Alessi; Leah Friedman; R Nisha Aurora; Brian Boehlecke; Terry Brown; Andrew L Chesson; Vishesh Kapur; Rama Maganti; Judith Owens; Jeffrey Pancer; Todd J Swick; Rochelle Zak
Journal:  Sleep       Date:  2007-11       Impact factor: 5.849

Review 7.  Circadian rhythm sleep disorders: part I, basic principles, shift work and jet lag disorders. An American Academy of Sleep Medicine review.

Authors:  Robert L Sack; Dennis Auckley; R Robert Auger; Mary A Carskadon; Kenneth P Wright; Michael V Vitiello; Irina V Zhdanova
Journal:  Sleep       Date:  2007-11       Impact factor: 5.849

Review 8.  The relevance of melatonin to sports medicine and science.

Authors:  Greg Atkinson; Barry Drust; Thomas Reilly; Jim Waterhouse
Journal:  Sports Med       Date:  2003       Impact factor: 11.136

9.  Melatonin inhibits ESCC tumor growth by mitigating the HDAC7/β-catenin/c-Myc positive feedback loop and suppressing the USP10-maintained HDAC7 protein stability.

Authors:  Zhi-Qiang Ma; Ying-Tong Feng; Kai Guo; Dong Liu; Chang-Jian Shao; Ming-Hong Pan; Yi-Meng Zhang; Yu-Xi Zhang; Di Lu; Di Huang; Fan Zhang; Jin-Liang Wang; Bo Yang; Jing Han; Xiao-Long Yan; Yi Hu
Journal:  Mil Med Res       Date:  2022-09-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.